AzurRx (AZRX) Corporate Media Kit

25 • Per Protocol Analysis Source: University of Adelaide, Adelaide, Australia; 2. AzurRx, Langlade, France; 3. Syneos Health, London, UK; 4. AzurRx, New York, NY, USA. Nam Q Nguyen , 1 Luc Lebreton, 2 Gary Smith, 3 Philippe Jais, 2 Mathieu Schue, 2 and Thijs Spoor 4 “Impact of a spray dried recombinant lipase, MS1819, For the treatment of exocrine pancreatic insufficiency in patients with chronic pancreatitis: Results of a multicenter, Phase II, open-label, non-randomized study”. Presented by Dr. Nam Q. Nguyen, et al., at Digestive Disease Week on May 20, 2019. * Per Protocol Analysis. Intent to Treat Analysis showed a Mean Change of 15.7%, p value <0.001 Baseline @ Highest Dose of MS1819-SD (2240 mg) Mean Change p-value Coefficient of Fat Absorption (CFA)* 41.2 63.3 21.8% 0.002 Stool Consistency (Bristol Scale) 5.1 4.1 -19.6% 0.006 Bowel Movements 2.8 1.9 -32% 0.006 Steatorrhea 12.3 10.1 -18% 0.008 Abdominal Discomfort (Visual Analog Scale) 21.0 14.5 -31% 0.148 MS1819 Phase 2 Study in CP: Primary and Secondary Efficacy Endpoints